T-helper type 2 immune response (Th2 response)

The T-helper type 2 (Th2) response is a specialized arm of the adaptive immune system primarily responsible for humoral immunity and defense against extracellular parasites, such as helminths (PubMed: 27142424). It is characterized by the secretion of specific cytokines, including Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13), which coordinate activities like B-cell isotype switching to IgE and the recruitment of eosinophils and mast cells (StatPearls: NBK541017). While protective in the context of infection, dysregulated or overactive Th2 responses are the fundamental drivers of 'Type 2-high' allergic and inflammatory diseases, including atopic dermatitis and allergic asthma (Nature Reviews Immunology: 10.1038/nri.2016.11). Pharmaceutical intervention focuses on neutralizing these cytokines or blocking their receptors to disrupt the inflammatory loop. For example, dupilumab targets the IL-4 receptor alpha subunit to inhibit both IL-4 and IL-13 signaling, significantly reducing clinical symptoms in patients with high Th2-driven disease burdens (NEJM: 10.1056/NEJMoa1700322). Because 'Th2 response' describes a complex physiological process involving multiple cellular and molecular components rather than a single protein, it is generally considered a pathway or biological phenotype rather than a discrete therapeutic target.

Other names

Type 2 immunityTh2-mediated immunityTh2 pathwayType 2 inflammatory response

Inhibition of Type 2 cytokines (IL-4, IL-5, IL-13) or their specific receptors and upstream activators (TSLP) to suppress the Th2-mediated inflammatory cascade.